The other side of the coin: Beneficiary effect of omega-3 fatty acids in sudden unexpected death in epilepsy

Disciplina de Neurologia Experimental, Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brasil.
Epilepsy & Behavior (Impact Factor: 2.06). 09/2008; 13(2):279-83. DOI: 10.1016/j.yebeh.2008.04.011
Source: PubMed

ABSTRACT The epilepsies are the most common serious neurological condition. People with epilepsy have a two- to threefold increased risk of dying prematurely than those without epilepsy, and the most common epilepsy-related category of death is sudden unexpected death in epilepsy (SUDEP). The exact pathophysiological causes of SUDEP remain unknown, but it is very probable that cardiac arrhythmia during and between seizures plays a potential role. Although the pharmacological treatments available for the epilepsies have expanded, antiepileptic drugs are still limited in clinical efficacy. In this regard, several factors such as genetic, environmental, and social can contribute to the inefficacy of therapeutic outcome in patients with epilepsy. Among these factors, nutritional aspects, that is, omega-3 fatty acid deficiency, have an interesting role in this scenario. Animal and clinical studies have demonstrated that omega-3 fatty acids may be useful in the prevention and treatment of epilepsy. Moreover, as omega-3 fatty acids per se have been shown to reduce cardiac arrhythmias and sudden cardiac deaths, it has been proposed that omega-3 fatty acid supplementation in patients with refractory seizures may reduce seizures and seizure-associated cardiac arrhythmias and, hence, SUDEP. Given their relative safety and general health benefits, our update article summarizes the knowledge of the role of dietary omega-3 fatty acids in epilepsy.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epilepsy is associated with a higher rate of premature death than the general population, and the commonest cause of epilepsy mortality is sudden unexpected death in epilepsy (SUDEP). It is difficult to quantify because of the variable reporting of this cause of death. Death occurs due to autonomic deregulation of cardio-respiratory pathways as a result of seizures. Measures to reduce cardio-respiratory dysfunction are discussed together with the importance of seizure control in preventing SUDEP. The role of seizure detection devices, antiepileptic drugs and the importance of providing information about SUDEP to people with epilepsy are highlighted. There is increasing interest in SUDEP and some current initiatives are discussed.
    Current Neurology and Neuroscience Reports 12/2014; 14(12):502. DOI:10.1007/s11910-014-0502-4 · 3.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study the fatty acid (FA) composition and lipid stability of wild and farm-affected wild bogues (Boops boops Linnaeus, 1758) during storage on ice were compared. The main saturated and unsaturated FAs were C16:0 and C18:1(n-9) in both bogue samples. Levels of eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3), and n-3/n-6 ratios, as well as atherogenic and thrombogenic indices, were significantly higher in wild samples. Over a period of 16 days on ice, the polyunsaturated fatty acids (PUFAs) were reduced by 9.4% in wild and by 11.7% in farm-affected wild bogues; however, lipid damage during storage on ice was low. The total free fatty acid content of wild and farm-affected wild bogues at three different stages during storage on ice was small, <3% over 16 days. Peroxide values changed from 1.05 to 5.73 and from 2.98 to 5.25 milliequivalents (meq)/kg of O2 in wild and farm-affected wild bogues, respectively, while thiobarbituric acid index stayed under 5 mg of malondialdehyde/kg in all samples. This work provides important information about the effect of farming activities on changes in lipid and nutritive properties of fish oil from wild and farm-affected wild bogue.
    Journal of Food Composition and Analysis 02/2015; 40. DOI:10.1016/j.jfca.2014.12.026 · 2.26 Impact Factor
  • Source
    Epilepsy & Behavior 09/2014; 41:21–22. DOI:10.1016/j.yebeh.2014.08.019 · 2.06 Impact Factor